ES-2 and HEY ovarian cancer cell lines exhibit activating mutations to the B-Raf oncogene and performed aggressively in an intra-peritoneal xenograft experimental model, supporting their classification as advanced-stage type I ovarian cancer cells [39], [40], [41]. The gene discussed is BRAF; the disease is ovarian cancer.